vs
中国东方航空（EML）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是中国东方航空的1.4倍（$75.5M vs $55.3M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -22.4%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $3.1M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -0.6%）
中国东方航空是中国境内的头部航空公司，总部位于上海长宁区，与中国国际航空、中国南方航空并称为中国三大骨干航空公司，航线网络覆盖全球多个国家和地区，是中国民航市场的核心运营商之一。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
EML vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.4倍
$55.3M
营收增速更快
PBYI
高出50.1%
-22.4%
自由现金流更多
PBYI
多$11.3M
$3.1M
两年增速更快
PBYI
近两年复合增速
-0.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $55.3M | $75.5M |
| 净利润 | $578.9K | — |
| 毛利率 | 22.3% | 69.3% |
| 营业利润率 | 3.1% | 22.7% |
| 净利率 | 1.0% | — |
| 营收同比 | -22.4% | 27.7% |
| 净利润同比 | 103.8% | — |
| 每股收益（稀释后） | $0.10 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMLPBYI
| Q4 25 | — | $75.5M | ||
| Q3 25 | $55.3M | $54.5M | ||
| Q2 25 | $70.2M | $52.4M | ||
| Q1 25 | $63.3M | $46.0M | ||
| Q4 24 | $64.3M | $59.1M | ||
| Q3 24 | $71.3M | $80.5M | ||
| Q2 24 | $72.6M | $47.1M | ||
| Q1 24 | $64.6M | $43.8M |
净利润EMLPBYI
| Q4 25 | — | — | ||
| Q3 25 | $578.9K | $8.8M | ||
| Q2 25 | $3.4M | $5.9M | ||
| Q1 25 | $1.9M | $3.0M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $-15.3M | $20.3M | ||
| Q2 24 | $3.5M | $-4.5M | ||
| Q1 24 | $1.9M | $-4.8M |
毛利率EMLPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | 22.3% | 77.7% | ||
| Q2 25 | 23.3% | 76.5% | ||
| Q1 25 | 22.4% | 77.1% | ||
| Q4 24 | 23.6% | 76.4% | ||
| Q3 24 | 25.5% | 63.9% | ||
| Q2 24 | 25.4% | 77.4% | ||
| Q1 24 | 23.9% | 75.5% |
营业利润率EMLPBYI
| Q4 25 | — | 22.7% | ||
| Q3 25 | 3.1% | 17.6% | ||
| Q2 25 | 4.5% | 12.7% | ||
| Q1 25 | 5.1% | 8.7% | ||
| Q4 24 | 6.1% | 22.6% | ||
| Q3 24 | 9.5% | 27.4% | ||
| Q2 24 | 8.3% | -4.6% | ||
| Q1 24 | 5.3% | -5.3% |
净利率EMLPBYI
| Q4 25 | — | — | ||
| Q3 25 | 1.0% | 16.2% | ||
| Q2 25 | 4.9% | 11.2% | ||
| Q1 25 | 3.1% | 6.5% | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | -21.5% | 25.2% | ||
| Q2 24 | 4.8% | -9.6% | ||
| Q1 24 | 3.0% | -11.0% |
每股收益（稀释后）EMLPBYI
| Q4 25 | — | $0.26 | ||
| Q3 25 | $0.10 | $0.17 | ||
| Q2 25 | $0.56 | $0.12 | ||
| Q1 25 | $0.32 | $0.06 | ||
| Q4 24 | $0.22 | $0.40 | ||
| Q3 24 | $-2.46 | $0.41 | ||
| Q2 24 | $0.56 | $-0.09 | ||
| Q1 24 | $0.31 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.2M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $124.3M | $130.3M |
| 总资产 | $220.0M | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资EMLPBYI
| Q4 25 | — | $97.5M | ||
| Q3 25 | $9.2M | $94.4M | ||
| Q2 25 | $9.1M | $96.0M | ||
| Q1 25 | $10.2M | $93.2M | ||
| Q4 24 | $16.1M | $101.0M | ||
| Q3 24 | $9.7M | $96.7M | ||
| Q2 24 | $2.0M | $96.8M | ||
| Q1 24 | $2.1M | $107.2M |
总债务EMLPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $42.2M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益EMLPBYI
| Q4 25 | — | $130.3M | ||
| Q3 25 | $124.3M | $115.3M | ||
| Q2 25 | $124.4M | $104.7M | ||
| Q1 25 | $121.0M | $97.1M | ||
| Q4 24 | $120.7M | $92.1M | ||
| Q3 24 | $119.2M | $71.1M | ||
| Q2 24 | $136.5M | $48.5M | ||
| Q1 24 | $134.5M | $51.0M |
总资产EMLPBYI
| Q4 25 | — | $216.3M | ||
| Q3 25 | $220.0M | $202.9M | ||
| Q2 25 | $229.4M | $194.9M | ||
| Q1 25 | $232.3M | $196.2M | ||
| Q4 24 | $235.3M | $213.3M | ||
| Q3 24 | $244.2M | $220.7M | ||
| Q2 24 | $255.9M | $205.0M | ||
| Q1 24 | $253.9M | $214.1M |
负债/权益比EMLPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.35× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $3.1M | $14.4M |
| 自由现金流率自由现金流/营收 | 5.5% | 19.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | 5.38× | — |
| 过去12个月自由现金流最近4个季度 | $12.3M | $41.7M |
8季度趋势，按日历期对齐
经营现金流EMLPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $3.1M | $9.7M | ||
| Q2 25 | $3.8M | $14.1M | ||
| Q1 25 | $-1.8M | $3.6M | ||
| Q4 24 | $11.0M | $15.6M | ||
| Q3 24 | $-2.9M | $11.0M | ||
| Q2 24 | $8.4M | $1.0M | ||
| Q1 24 | $2.8M | $11.2M |
自由现金流EMLPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $3.1M | $9.7M | ||
| Q2 25 | $3.0M | $14.1M | ||
| Q1 25 | $-2.7M | $3.6M | ||
| Q4 24 | $9.0M | $15.6M | ||
| Q3 24 | $-7.7M | $11.0M | ||
| Q2 24 | $7.3M | $1.0M | ||
| Q1 24 | $1.1M | — |
自由现金流率EMLPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | 5.5% | 17.7% | ||
| Q2 25 | 4.3% | 26.8% | ||
| Q1 25 | -4.3% | 7.7% | ||
| Q4 24 | 13.9% | 26.4% | ||
| Q3 24 | -10.8% | 13.7% | ||
| Q2 24 | 10.1% | 2.1% | ||
| Q1 24 | 1.7% | — |
资本支出强度EMLPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | 1.1% | 0.0% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 3.2% | 0.0% | ||
| Q3 24 | 6.7% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 2.6% | 0.0% |
现金转化率EMLPBYI
| Q4 25 | — | — | ||
| Q3 25 | 5.38× | 1.10× | ||
| Q2 25 | 1.09× | 2.41× | ||
| Q1 25 | -0.95× | 1.21× | ||
| Q4 24 | 8.41× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | 2.40× | — | ||
| Q1 24 | 1.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
